Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2025-04-24

FDA Approved: ZYRTEC HIVES — Supplemental Application (Kenvue Brands LLC)

View source ↗

Summary

FDA supplemental application for ZYRTEC HIVES to support labeling for cetirizine hydrochloride in the treatment of urticaria (hives).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ZYRTEC HIVES (cetirizine hydrochloride)

Snippet

SUPPL AP for ZYRTEC HIVES (CETIRIZINE HYDROCHLORIDE)